OrsoBio

OrsoBio, Inc. is a privately held clinical-stage biopharmaceutical company dedicated to developing therapies for severe metabolic diseases, including type 2 diabetes, severe dyslipidemia, steatosis, and non-alcoholic steatohepatitis (NASH). The company was co-founded by Mani Subramanian, M.D., Ph.D., former head of Gilead Sciences' liver disease therapeutic area, and Samsara BioCapital. OrsoBio currently has four programs in clinical and preclinical development stages, with its first-in-class compounds targeting central pathways of energy metabolism.